November 27, 2007: Stronger Warnings Urged for Tamiflu
Manufacturer Roche Laboratories, Inc. should update Tamiflu labeling to include stronger warnings regarding the risk of psychiatric problems in users of the flu medicine, according to a U.S. Food and Drug Administration (FDA) committee. The FDA Pediatric Advisory Committee made its recommendations after evaluating reports of adverse events associated with use of the prescription influenza medication -- including delusions, confusion, and self-injury -- especially in children.

November 13, 2006: Tamiflu Prescribing Information Changed to Reflect Reports of Odd Behavior
Roche Laboratories, Inc. and the U.S. Food and Drug Administration (FDA) notified healthcare professionals of revisions to Tamiflu's prescribing information. The changes reflect news reports (mostly from Japan) of self-injury and delirium with the use of Tamiflu in patients with influenza. People with the flu (particularly children) may be at risk of self-injury and confusion shortly after taking Tamiflu, and should be monitored closely for signs of unusual behavior. Click here for more information from the FDA.